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ABSTRACT
Peroxisome proliferator-activated receptor c
(PPARc) is a key transcription factor in mamma-
lian adipogenesis. Genome-wide approaches
have identified thousands of PPARc binding sites
in mouse adipocytes and PPARc upregulates
hundreds of protein-coding genes during adipo-
genesis. However, no microRNA (miRNA) genes
have been identified as primary PPARc-targets. By
integration of four separate datasets of genome-
wide PPARc binding sites in 3T3-L1 adipocytes we
identified 98 miRNA clusters with PPARc binding
within 50kb from miRNA transcription start sites.
Nineteen mature miRNAs were upregulated 2-fold
during adipogenesis and for six of these miRNA loci
the PPARc binding sites were confirmed by at least
three datasets. The upregulation of five miRNA
genes miR-103-1 (host gene Pank3), miR-148b
(Copz1), miR-182/96/183, miR-205 and miR-378
(Ppargc1b) followed that of Pparg. The PPARc-
dependence of four of these miRNA loci was
demonstrated by PPARc knock-down and the loci
of miR-103-1 (Pank3), miR-205 and miR-378
(Ppargc1b) were also responsive to the PPARc
ligand rosiglitazone. Finally, chromatin immunopre-
cipitation analysis validated in silico predicted
PPARc binding sites at all three loci and H3K27
acetylation was analyzed to confirm the activity of
these enhancers. In conclusion, we identified 22
putative PPARc target miRNA genes, showed the
PPARc dependence of four of these genes and
demonstrated three as direct PPARc target genes
in mouse adipogenesis.
INTRODUCTION
The need for understanding of the mechanisms controlling
the differentiation of ﬁbroblast-like pre-adipocytes to
lipid-loaded adipocytes is due to the worldwide epidemic
of obesity of high medical relevance (1). Adipogenesis is
regulated by a network of transcription factors. The most
prominent transcription factor in adipocytes is the nuclear
receptor peroxisome proliferator-activated receptor g
(PPARg) (2). During mouse adipogenesis the number of
genomic binding sites for PPARg increases from a few
to thousands (3–7) implicating that PPARg regulates
hundreds of genes during adipogenesis. Therefore, the
synthetic PPARg ligand rosiglitazone (RGZ) has been
used in many countries in the therapy of type 2 diabetes
mainly acting via its effects on gene regulation in adipo-
cytes (8).
The prerequisite for the direct transcriptional regula-
tion of a given gene by PPARg is the presence of at
least one speciﬁc PPARg binding site, referred to
as PPAR response element (PPRE), in the regulatory
regions ﬂanking the gene’s transcription start site (TSS)
[reviewed in (9)]. Direct DNA binding of PPARg takes
place as a heterodimeric complex with another nuclear
receptor, the retinoid X receptor (RXR), and PPREs
are formed as a direct repeat of hexameric core binding
motifs with one intervening nucleotide (DR1-type
PPREs) (10,11). To promote the expression of its target
genes, PPARg must overcome the transcriptionally
repressive dense packaging of genomic DNA within
chromatin. PPARg is also capable of repressing some of
its target genes in a ligand-dependent manner either
directly via recruitment of co-repressors upon agonist
binding or via a mechanism called trans-repression
(12,13). However, in adipocytes PPARg has been mainly
linked to transcriptional activation of its target genes
(3–5).
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several new groups of small RNA molecules have been
described in recent years as capable of controlling gene
expression [reviewed in (14)]. One of the most important
of these groups consists of small RNA molecules called
microRNAs (miRNAs), which are endogenous non-
coding transcripts transcribed mainly by RNA polymerase
II (RNA Pol II) as their own primary transcripts
(pri-miRNAs) or together with their host genes
[reviewed in (15)]. The miRNA precursor (pre-miRNA)
is cropped from the primary transcript by a complex
known as Microprocessor that consists of two proteins,
namely DROSHA and DGCR8. This pre-miRNA hairpin
is then further processed into the mature miRNA duplex
by an RNase III enzyme DICER. The mature miRNAs
can identify their target mRNAs by base pairing to the
partially complementary regions within the target mRNAs
(16). miRNAs function by serving as guides to the
proteins of the Argonaute family and other associated
proteins, which together induce inhibition of translation
as well as degradation of the targeted mRNAs (17,18).
Currently, there are more than 700 known mature
miRNAs in mouse (miRBase v18.0) and most of them
can potentially target hundreds of mRNAs (19,20).
In this way they show very comparable functions to tran-
scription factors. Thus miRNAs can remarkably inﬂuence
the transcriptomes of most eukaryotic cells. Still, fairly
little is known about the transcriptional regulation of
miRNA genes. Until recently, the progress was
hampered by limited knowledge about the structure of
miRNA genes, especially the location of their TSSs
(21,22). Many miRNAs are transcribed together as
clusters of several mature miRNAs. Considering this
feature and the fact that each of these miRNAs can
have a potential to regulate a vast number of target
mRNAs, the transcriptional control of these miRNA
genes needs to be both accurate and robust. And import-
antly, miRNAs have been shown to play key roles in the
development and differentiation of most tissues and cell
types (23). Also the formation of white adipose tissue
in vivo and the differentiation of the mouse pre-adipocyte
cell line 3T3-L1 depend on expression of miRNAs (24,25).
Moreover, some miRNAs, such as miR-103, are regula-
tors of adipogenesis in mouse (26).
Several recent datasets of chromatin immunopre-
cipitation (ChIP)-based monitoring of genome-wide
binding of PPARg during differentiation of 3T3-L1 cells
identiﬁed thousands of genomic PPARg-bound sites sug-
gesting hundreds of PPARg target genes (3–7). However,
none of these are miRNA genes. Therefore, in this study
we integrated four of the above mentioned datasets of
genome-wide PPARg binding sites and mouse miRNA
TSS annotations (3–6,21) and identiﬁed 98 miRNA
clusters with PPARg binding within 50kb from
miRNA gene TSSs. Nineteen of these miRNAs (corres-
ponding to 22 miRNA genes) are upregulated during
adipogenesis and are putative PPARg targets. Further
ﬁltering resulted in the ﬁve miRNA genes miR-103-1
(host gene Pank3), miR-148b (Copz1), miR-182/96/183,
miR-205 and miR-378 (Ppargc1b) that followed the
upregulation of the Pparg gene during mouse
adipogenesis. The transcription of all except miR-148b
(Copz1) depends on PPARg in adipocytes and the loci
of miR-103-1, miR-205 and miR-378 were also responsive
to RGZ. Finally, ChIP assays validated three in silico pre-
dicted PPREs at the miR-103-1 locus, two at the miR-378
locus, and one at the miR-205 locus. In conclusion, we
have identiﬁed a number of PPARg-regulated miRNA
genes in mouse adipogenesis, which will serve the future
integration of miRNAs to the core regulatory network of
adipocyte differentiation and further characterize the
extensive role of PPARg during this process.
MATERIALS AND METHODS
Integration of the genome-wide PPARc binding data
and miRNA TSS annotation
The different publically available datasets used in this
study were uniﬁed on a common genome build on the
basis of the coordinates from TSS annotation data for
miRNA genes from Marson et al. (21), namely NCBI36/
mm8. Accordingly, the coordinates of the PPARg-bound
sites from Nielsen et al. (4) and Lefterova et al. (6) were
lifted over from mm9 to mm8 using the UCSC lift-over
tool, while the coordinates from the datasets of Lefterova
et al. (3) and Hamza et al. (5) were already based on mm8.
For all datasets we used only published pre-analyzed data
and the provided coordinates for PPARg-bound sites were
used. First, miRNA gene TSSs within 50kb of a PPARg
binding site (Supplementary Table S1A–D) were
identiﬁed. This was followed by checking whether an
identiﬁed PPARg binding site overlaps with an in silico
predicted PPRE (10) (Supplementary Table S2A–D).
A third step detects, whether an identiﬁed PPARg
binding site co-localizes with a CEBPa (CCAAT/
enhancer binding protein) binding site. As input data for
the last step, PPARg- and CEBPa-bound sites provided
by Lefterova et al. (3) were used and a threshold of 1kb
was applied to deﬁne a co-localized region. Further details
can be provided upon request.
Cell culture
The 3T3-L1 mouse pre-adipocyte cell line was used for all
experiments. The cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal
calf serum, 1% penicillin–streptomycin and 1% L-glutam-
ine. The cells were kept at 37C and 5% CO2. In order to
differentiate pre-adipocytes to adipocytes, the cells were
seeded 4 days before differentiation (D-4), grown 2 days
to reach conﬂuency (D-2) and maintained 2 days
post-conﬂuency before starting the differentiation (D0)
by adding differentiation medium I (500mM 3-isobutyl-
1-methylxanthine, 250nM dexamethasone and 5mg/ml
insulin in normal growth medium). From D2 on differen-
tiation medium II (5mg/ml insulin and 100nM RGZ in
normal growth medium) was used and renewed every 2
days (D4, D6). For treatments with RGZ and
5,6-Dichlorobenzimidazole 1-b-D-ribofuranoside (DRB)
the cells were seeded and grown in the same way as
described above. Two or six days differentiated 3T3-L1
mouse cells were treated either with 100nM RGZ
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control [dimethyl sulfoxide (DMSO)] and total RNA was
collected after 4, 8, 12, 24 and 48h.
siRNA silencing
Six days differentiated 3T3-L1 cells were transfected with
Nucleofector II Device (Lonza, Basel, Switzerland) by
using Cell Line Nucleofector Kit V and program A-033.
The transfection procedure was done according to the
manufacturer’s instructions using a 100nM mixture of
three double-stranded siRNA sequences against Pparg
(siPparg, Eurogentec, Liege, Belgium) or 100nM of a
scrambled double-stranded siRNA sequence as a control
(siControl, Eurogentec). The cells were collected 48h
post-transfection. The siRNA sequences are provided in
Supplementary Table S3.
RNA extraction and cDNA synthesis
Total RNA was isolated from the 3T3-L1 cells by using
TRIsure (Bioline, London, UK). Medium was removed
and 1ml of TRIsure per 6-well plates was added to lyse
the cells. RNA was extracted with 200ml chloroform
andprecipitatedfromtheaqueousphasewith400mlisopro-
panol by incubating at 20C overnight. cDNA
was synthesized by using 1mg of total RNA, 0.5mM
dNTPs, 2.5mM oligo-dT primer (for mature mRNAs) or
0.2mg random hexamer primers (for pri-miRNAs), 1 U/ml
RiboLockRNaseInhibitor(Fermentas,Vilnius,Lithuania)
and 10 U/ml M-MuLV Reverse Transcriptase (Fermentas).
The cDNA synthesis was performed for 1h at 37C and
the reaction was stopped by 10min incubation at 70C.
Quantitative PCR
Real-time quantitative PCR (qPCR) was performed in an
Applied Biosystems 7500 Fast Real-Time PCR System
using Absolute Blue qPCR SYBR Green Low ROX Mix
(Thermo Fisher Scientiﬁc, Surrey, UK). For each reaction
5ml of cDNA template or 4ml of ChIP template, 1mlo f
primer pairs (10mM) and 10ml of the qPCR SYBR
mixture to a ﬁnal reaction volume of 20ml were used.
The PCR reaction started with 15min at 95Ct o
activate the polymerase. The PCR cycling conditions
were: 40 cycles, of which each was composed of 15s at
95C, 15s at 55C and 30s at 72C. Relative expression
levels at the tested experimental conditions were calculated
within each independent experiment using the formula
2
(Ct), where Ct is (Ct(target gene)Ct(Rpl13a))tested
condition(Ct(target gene)Ct(Rpl13a))control condition and the
Ct is the cycle, at which the threshold is crossed.
Depending on the experiment either vehicle control,
siCtrl or D0 served as the control condition. The quality
of the PCR product was monitored using post-PCR melt
curve analysis. The sequences of the primer pairs are listed
in Supplementary Table S4 and a schematic depiction of
their locations is provided in Supplementary Figure S1.
miRNA assays
The detection of the miRNAs was done by using TaqMan
MicroRNA Reverse Transcription Kit together with
TaqMan MicroRNA Assays (Applied Biosystems). The
miRNA cDNA synthesis and miRNA detection was
done by following the manufacturers instructions and by
using an Applied Biosystems 7500 Fast Real-Time PCR
System. Relative expression levels at the tested experimen-
tal conditions were calculated within each independent
experiment using the formula 2
(Ct), where Ct
is (Ct(target miRNA)Ct(U6))tested condition(Ct(target
miRNA)Ct(U6))control condition and the Ct is the cycle, at
which the threshold is crossed. Depending on the experi-
ment either vehicle control, siCtrl or D0 served as the
control condition.
ChIP
ChIP was performed using conﬂuent 3T3-L1 pre-
adipocytes (D0) or 3T3-L1 adipocytes (D6) grown on
10cm
2 dishes. Chromatin was cross-linked by adding for-
maldehyde at Enal concentration of 1% to the culture
media for 8min. The cross-linking reaction was stopped
with 150mM glycine for 5min. The cells were washed
twice with phosphate-buffered saline (PBS) and lysed in
650ml SDS lysis buffer (1% SDS, 10mM EDTA, 50mM
Tris–HCl, pH 8.1) containing a protease inhibitor cocktail
(Roche Diagnostics, Mannheim, Germany). In order to
reduce the DNA to average length of 500bp, the lysates
were sonicated (Bioruptor, Diagenode, Liege, Belgium)
with 1530s pulses. Cellular debris were removed by cen-
trifugation and the lysates were diluted 1:10 in ChIP
dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2mM
EDTA, 167mM NaCl, protease inhibitors and 16.7mM
Tris–HCl, pH 8.1). A quantity of 1500ml of diluted lysate
were incubated with the respective antibody [3.5ml
anti-PPARg (101700, Cayman, Ann Arbor, MI USA),
5ml anti-PPARg (sc-7196, Santa Cruz Biotechnologies,
Santa Cruz, CA, USA) or 2.5ml IgG (sc-2027)] overnight
at 4C. The immuno-complexes were collected with 60ml
of BSA-coated protein A agarose beads slurry (Millipore,
Billerica, MA, USA) for 2h at 4C with rotation. The
beads, containing the immuno-complexes, were washed
sequentially with 1ml of the following buffers: low salt
wash buffer (0.1% SDS, 1% Triton X-100, 2mM
EDTA, 150mM NaCl, 20mM Tris–HCl, pH 8.1), high
salt wash buffer (0.1% SDS, 1% Triton X-100, 2mM
EDTA, 500mM NaCl, 20mM Tris–HCl, pH 8.1), LiCl
wash buffer (0.25mM LiCl, 1% Nonidet P-40, 1%
sodium deoxycholate, 1mM EDTA, 10mM Tris–HCl,
pH 8.1) and twice with TE buffer (1mM EDTA, 10mM
Tris–HCl, pH 8.0). After the washing steps the
immuno-complexes were eluted with 500ml elution buffer
(1% SDS, 100mM NaHCO3). The cross-linking was
reversed with proteinase K (40mg/ml, Fermentas) over-
night at 65C. The DNA was recovered by
phenol-chloroform extraction or by ChIP DNA Clean
Kit (Zymo Research, Irvine, CA, USA), ethanol
precipitated and dissolved in 60ml of water. Sample of
4ml were used as template for qPCR using speciﬁc
primers listed in Supplementary Table S4. Relative enrich-
ment was calculated using the formula 2
(Ct) where
Ct is (Ct(PPARg)Ct(input))(Ct(IgG)Ct(input)),
PPARg and IgG are the respective immunoprecipitated
4448 Nucleic Acids Research, 2012,Vol.40, No. 10DNA samples and input is 1:100 diluted puriﬁed genomic
DNA from the starting material of the respective
immunoprecipitation.
Western blot
Cells, seeded in 6-well plates, were ﬁrst washed with PBS,
trypsinized for 5min at 37C and centrifuged. The remain-
ing pellet was lysed in 200ml ice-cold protein lysis buffer
(150mM NaCl, 1mM EDTA, 1% Triton-X, 20mM Tris–
HCl, pH 7.4) containing protease inhibitors (Roche
Diagnostics). Then the lysate was sonicated at low fre-
quency with 10 repeats of 8s pulses followed by 30s
pauses. Sonicated lysates were centrifuged for 30min at
maximum speed to separate the fat from the proteins and
the cell debris. The protein concentrations were measured
by Bradford assay and comparable amounts were loaded
on a gel. The proteins were separated with SDS–PAGE,
probed with the corresponding primary (anti-PPARg,
1:200 dilution (101700 Cayman), anti-b-actin, 1:10,000
dilution (MAB1501, Millipore) and horseradish pero-
xidase-coupled secondary antibodies (anti-mouse IgG,
1:500 dilution (P0447, Dako, Glostrup, Denmark) and
anti-rabbit IgG, 1:500 dilution (P0448, Dako)) and dete-
cted via ECL (GE Healthcare, Buckinghamshire, UK).
RESULTS
PPARc localization at miRNA loci in mouse adipocytes
In order to identify miRNA genes regulated by PPARg in
mouse adipogenesis, we integrated the genome-wide
binding site coordinate information from four available
datasets (3–6) with the recent TSS annotation of mouse
miRNA genes (21) (Table 1). The considered binding sites
were selected according to the analysis in the original pub-
lications (3–6). The total number of PPARg-bound sites in
the differentiated 3T3-L1 adipocytes varied for each
dataset from approximately 2600 to almost 7000. We
screened each of the four datasets for miRNA genes that
had at least one PPARg-bound site within ±50kb from
their TSS (Supplementary Table S1). Under these criteria
for each dataset between 22 and 70 miRNA clusters (cor-
responding to 31–113 miRNA precursors) were identiﬁed.
Combining the information from all four datasets resulted
in 98 different miRNA clusters (corresponding to 149 in-
dividual miRNA precursors and 140 different mature
miRNAs, Table 1). Within these 98 genomic loci 61
miRNA genes had at least one of their observed
PPARg-bound sites overlapping with a putative PPRE
identiﬁed in silico by RESearch algorithm (10)
(summarized in Table 1, details are in Supplementary
Table S2). This suggests that in majority of the loci the
PPARg enrichment corresponds to direct DNA binding.
In summary, we integrated genome-wide datasets for
PPARg binding with the location of miRNA gene
TSSs and identiﬁed 149 pre-miRNAs corresponding to
140 mature miRNAs in 98 genomic loci with at least
one PPARg binding site within 50kb distance to their
TSS.
Identiﬁcation of putative PPARc target miRNA genes
To better distinguish, which of the miRNA genes with
PPARg binding in their vicinity could be direct targets
of PPARg, we compared the list of 140 mature miRNAs
combined from all four datasets (originating from 149
precursors; Table 1) to the existing miRNA expression
proﬁling from 3T3-L1 adipocytes (26) (Figure 1A).
Applying a 2-fold cut-off, a similar number of miRNAs
were up- and downregulated (26 and 19, respectively)
during 9 days of adipogenesis. Comparing these miRNA
lists with the combined list of 140 mature miRNAs
(Table 1) showed that a total of 19 different mature
miRNAs associated with PPARg binding in at least one
of the datasets were also upregulated above 2-fold during
3T3-L1 adipogenesis (Figure 1A). Nine different miRNAs
showed similar extent of downregulation. Interestingly,
the miRNA genes with PPARg-bound sites were signiﬁ-
cantly enriched for upregulated miRNAs (calculated using
hypergeometric probability, P=1.0310
5). This en-
richment of upregulated miRNAs ﬁts well with the role
of PPARg as a transcriptional activator of its target genes
(3–5) and implies that many of these miRNAs could be
real targets of PPARg-mediated regulation.
Since many mature miRNAs can be transcribed from
more than one locus, but cannot be distinguished by
sequence in miRNA microarray analysis, the number of
miRNA genes that are putative primary PPARg targets is
22, i.e. it exceeds that of the identiﬁed mature miRNAs. In
addition, many of these putative PPARg target miRNA
genes give rise to more than one mature miRNA. This
opens the possibility that also the other miRNAs that
are transcribed from these clusters are regulated by
PPARg, although they did not change above 2-fold in
the array analysis.
Table 1. Genome-wide PPARg occupancy close to miRNA gene TSSs
Dataset Total # of PPARg
peaks
# of miRNA precur-
sors with PPARg peak
(±50kb)
# of miRNA clusters with
PPARg peak (±50kb)
# of miRNA clusters
with PPARg peaks
overlapping PPREs
Lefterova et al. (3) (ChIP-chip) 5299 77 52 36
Nielsen et al. (4) (ChIP-Seq) 6946 113 70 45
Hamza et al. (5) (ChIP-PET) 2953 49 35 1
Lefterova et al. (6) (ChIP-Seq) 2611 31 22 12
All combined – 149 98 61
The annotation of miRNA TSS is based on Marson et al. (21).
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PPARg among the putative target miRNAs, we analyzed
how many of all of the miRNA genes are implicated as
PPARg targets in at least three of the four used genome-
wide binding proﬁle datasets. The direct overlapping of
the exact PPARg binding site genomic coordinates from
the four different datasets rarely show direct matches,
although the same antibody has been used in all four
studies (data not shown). These differences are likely to
be explained by the rather different methodology and
varying data analysis strategies. In order to overcome
this issue, we checked how many of the PPARg-associated
miRNAs (Supplementary Table S1) were common
between the different datasets. Ten miRNAs were
located in loci bound by PPARg in all four genomic
PPARg binding site datasets and another 19 in at least
three of the four datasets (Supplementary Figure S2).
From these 29 miRNAs, 27 were mature miRNAs with
different sequences and could be distinguished in miRNA
microarray analysis. Overlapping the list of these mature
miRNAs with the miRNAs downregulated in adipocytes
yielded only one mature miRNA (Figure 1B). However,
ﬁve mature miRNAs miR-103, miR-148b, miR-183,
miR-205 and miR-378, originating from six separate
miRNAs genes, were upregulated above 2-fold in adipo-
cytes. These constitute the high conﬁdence PPARg target
miRNA genes in mouse adipocytes and are referred to as
the candidate PPARg target miRNAs from here on.
Taken together, further ﬁltering of miRNA genes with
PPARg-bound sites that were both conﬁrmed in at least
three genome-wide datasets and upregulated at least
2-fold during adipogenesis reduced the list to the ﬁve
miRNAs miR-103, miR-148b, miR-183, miR-205 and
miR-378.
Dynamic expression proﬁles of the candidate
PPARc-target miRNAs and their host genes during
adipocyte differentiation
The ﬁve candidate PPARg target miRNAs originate from
six different miRNA loci, since miR-103 is transcribed
from two different loci, miR-103-1 and miR-103-2, as
two identical mature miRNAs. miR-103-1, miR-103-2,
miR-148b and miR-378 are transcribed within their re-
spective host genes Pank3, Pank2, Copz1 and Ppargc1b.
None of these host genes have so far been described as
A
B
miRNAs with PPARγ binding 
within 50 kb from TSS (140)
miRNAs down-regulated 
≥ 2.0-fold during 3T3-L1 
differentiation (19)
miRNAs up-regulated 
≥ 2.0-fold during 
3T3-L1 differentiation (26)
High confidence PPARg  target miRNA genes (6):
mmu-miR-103-1
mmu-miR-103-2
mmu-miR-148b
mmu-miR-182/miR-96/miR-183
mmu-miR-205
mmu-miR-378
miRNAs with PPARγ binding within 50 kb 
from TSS in ≥ 3 datasets (27)
miRNAs down-regulated 
≥ 2.0-fold during 3T3-L1 
differentiation (19)
miRNAs up-regulated 
≥ 2.0-fold during 
3T3-L1 differentiation (26)
Putative PPARg  target miRNA  genes  (22):
mmu-let7a-1/let-7f-1/let-7d mmu-miR-182/miR-96/miR-183
2 - 5 6 3 / 3 9 1 - R i m - u m m g 7 - t e l - u m m
mmu-miR-101b mmu-miR-193b/miR-365-1
mmu-miR-103-1 mmu-miR-194-1/miR-215
mmu-miR-103-2 mmu-miR-194-2/miR-192
mmu-miR-107 mmu-miR-205
mmu-miR-10b mmu-miR-210
mmu-miR-146b mmu-miR-30a
mmu-miR-148a mmu-miR-30c-1/miR-30e
mmu-miR-148b mmu-miR-30c-2
mmu-miR-15a/miR-16-1 mmu-miR-378
Figure 1. Dataset integration to identify the putative PPARg target miRNAs. (A) A Venn diagram depicting the overlapping of the list of all
individual mature miRNAs (140) with PPARg binding within 50kb from their TSS (Supplementary Table S1) together with >2-fold up or
downregulated miRNAs based on available miRNA expression proﬁling during 3T3-L1 differentiation (26). This analysis yields 19 upregulated
mature miRNAs that are putative PPARg targets. The 22 putative PPARg target miRNA genes corresponding to the 19 mature miRNAs (in bold)
are listed on the right side. (B) A Venn diagram depicting the overlapping of the list of all individual mature miRNAs (27) with PPARg binding
within 50kb from their TSS (Supplementary Figure S2) in at least three of the used datasets together with >2-fold up or downregulated miRNAs
based on available miRNA expression proﬁling during 3T3-L1 differentiation. This analysis yields ﬁve upregulated mature miRNAs that are high
conﬁdence PPARg targets. The six putative PPARg target miRNA genes corresponding to the ﬁve mature miRNAs (in bold) are listed on the
right side.
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transcribed from intergenic regions, most likely as inde-
pendent miRNA genes. In addition, miR-183 is part of a
cluster of three mature miRNAs and is transcribed
together with the two other members of the cluster,
miR-182 and miR-96.
Due to the very short sequence of the mature miRNAs,
the arrays used to measure miRNA expression proﬁles are
often prone to false positive results. In order to validate
the upregulation and to analyze the expression dynamics
of the six candidate PPARg target miRNAs as well as
their host genes, we proﬁled their expression and
compared them with the positive control genes Pparg,
Cebpa and Angptl4 during mouse adipogenesis. To do
this we took every 24h RNA samples from the 8-day dif-
ferentiation process of 3T3-L1 cells and determined by
qPCR the relative expression of the transcripts of
interest (Figure 2A). For each miRNA we measured the
levels of the mature miRNA as well as the pri-miRNA.
While the exact fold changes between independent differ-
entiation experiments vary, the overall expression proﬁles
of individual transcripts were generally reproducible
(Figure 2B–G). This was conﬁrmed by ANOVA analysis
for signiﬁcant changes during the time course, which con-
ﬁrmed the changes for all tested mRNAs and most of the
microRNAs as statistically signiﬁcant (Figure 2).
The robust upregulation of the Pparg gene was visible
already on D2 and conﬁrmed the successful differentiation
of the adipocytes (Figure 2B). The expression proﬁles of
the two known primary PPARg target genes, Cebpa and
Angptl4 (27,28), followed closely that of Pparg. All three
genes were clearly induced by D4 and remained at induced
levels through the remaining time course (Figure 2B).
Mature miR-103-1 and miR-103-2 are produced from
intron 5 of two separate but related host genes encoding
the pantothenate kinases PANK3 and PANK2, respect-
ively. These enzymes are important for co-enzyme
A synthesis and thereby for lipid metabolism (29). The
level of mature miR-103 continuously increased through
the differentiation starting from D2 to >5-fold on D8
(Figure 2C). Consistent with previous reports, the Pank2
gene showed no or only weak upregulation during
adipogenesis when compared with the level of Pank3
mRNA that robustly increased with an expression
proﬁle similar to that of the known PPARg target gene
Cebpa (Figure 2C) (26). This indicates that the observed
increase in miR-103 is mainly due to increased production
of miR-103-1 from the Pank3 gene locus. This observation
is further supported by the fact that pri-miR-103-1 is
clearly induced during adipogenesis while pri-miR-103-2
remained non-induced in most experiments. Interestingly,
the upregulation of the mature miR-103 showed a delay in
relation to its host gene Pank3. This might reﬂect the
different processing and stability of the miRNA
compared with the mRNA as well as the fact that tran-
scription at the Pank3 locus has to triple in order to lead
to doubling in the mature miR-103 production due to very
similar basal expression levels of the two miR-103 loci
(data not shown, see also ‘Discussion’ section).
Unlike for miR-103, the initial induction of miR-148b
slightly preceded that of its host gene Copz1 and showed a
peak after D6 of differentiation (Figure 2D). Both
miR-148b and its host gene Copz1 were upregulated
more moderately than the other tested PPARg target
genes and for Copz1 (and the pri-miR-148b) the fold
change never exceeded 3-fold. The upregulation of
miR-96 was fairly robust reaching maximum induction
around D8 of differentiation and resembling the delayed
induction of miR-103 (Figure 2E). However, the expres-
sion proﬁle of pri-miR-96 suggests that the locus is tran-
scriptionally activated already at earlier stages of
differentiation.
By far the most induced of all the tested miRNAs was
miR-205 that had strongly increased already on D3 of
differentiation and reached several hundred-fold induc-
tion by the end of the differentiation (Figure 2F). The
extent of the induction can be explained by the very low
basal expression of miR-205 in pre-adipocytes (data not
shown). Similarly to the mature miRNA, also pri-miR-205
was upregulated during the time course, although with
lower fold change. This argues that increased transcrip-
tional activity at the miR-205 locus is contributing to the
robust observed induction of the mature miRNA, while
speciﬁc regulation of the miRNA biogenesis pathway
might also play a role.
The upregulation of miR-378 was the second highest of
all the miRNAs tested (Figure 2G). The host gene of
miR-378, Ppargc1b, encodes for PGC-1b, which is an
important transcriptional co-activator of PPARg as well
as other transcription factors (30,31). Ppargc1b expression
was induced already early on with a very similar proﬁle to
known PPARg target genes, followed by strong increase in
pri-miR-378. The mature miR-378 followed the expression
of the host gene and the primary transcript, leading again
to slightly delayed response by the mature miRNA.
In general, the pri-miRNAs showed quite different
dynamics from their respective mature miRNAs, and
especially for miR-205, these inductions were clearly
weaker. These differences may be explained by the rela-
tively low stability of the transient pri-miRNA transcripts
that are processed into pre-miRNAs co-transcriptionally
(32,33). To address this possibility in more detail we
speciﬁcally inhibited RNA Pol II-mediated transcriptional
elongation in D6 adipocytes by treating the cells
with DRB for a time course of 12, 24 and 48h (Supple-
mentary Figure S3A). As expected, all tested mRNAs had
decreased by around 50% or more already after 12h and
remained at lowered levels throughout the treatment
(Supplementary Figure S3B–G). Cebpa and Pparg were
the least stable mRNAs with only 5–20% of the tran-
scripts remaining after DRB treatment when compared
with cells similarly treated with the DMSO vehicle
(Supplementary Figure S3B). Similarly to mRNAs, the
pri-miRNA transcripts were all reduced up to 10-fold
after 12h of transcription inhibition and for all except
pri-miR-103-2 remained below the control levels
(Supplementary Figure S3B–G). Curiously, all pri-
miRNA transcripts exhibited some increase in their
levels towards the end of the treatment. This might to be
explained by decreased processing of the primary tran-
scripts upon prolonged inhibition of RNA Pol II. In
contrast to the unstable pri-miRNA transcripts, most of
Nucleic Acids Research, 2012,Vol.40, No. 10 4451A
B
C
D
E
F
G
F
i
g
u
r
e
2
.
E
x
p
r
e
s
s
i
o
n
p
r
o
ﬁ
l
e
s
o
f
t
h
e
c
a
n
d
i
d
a
t
e
P
P
A
R
g
t
a
r
g
e
t
m
i
R
N
A
s
a
n
d
h
o
s
t
g
e
n
e
s
d
u
r
i
n
g
8
d
a
y
s
o
f
3
T
3
-
L
1
m
o
u
s
e
p
r
e
-
a
d
i
p
o
c
y
t
e
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
.
q
P
C
R
w
i
t
h
g
e
n
e
-
s
p
e
c
i
ﬁ
c
p
r
i
m
e
r
s
f
o
r
m
i
R
N
A
h
o
s
t
g
e
n
e
s
a
n
d
t
h
e
p
r
i
-
m
i
R
N
A
s
o
r
T
a
q
M
a
n
p
r
o
b
e
s
f
o
r
t
h
e
m
a
t
u
r
e
m
i
R
N
A
s
w
e
r
e
u
s
e
d
t
o
m
e
a
s
u
r
e
t
h
e
e
x
p
r
e
s
s
i
o
n
p
r
o
ﬁ
l
e
s
o
f
t
h
e
d
i
f
f
e
r
e
n
t
t
r
a
n
s
c
r
i
p
t
s
d
u
r
i
n
g
8
d
a
y
s
o
f
3
T
3
-
L
1
m
o
u
s
e
p
r
e
-
a
d
i
p
o
c
y
t
e
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
.
S
c
h
e
m
a
t
i
c
d
e
p
i
c
t
i
o
n
s
o
f
t
h
e
l
o
c
a
t
i
o
n
s
o
f
q
P
C
R
p
r
i
m
e
r
s
a
r
e
p
r
o
v
i
d
e
d
i
n
S
u
p
p
l
e
m
e
n
t
a
r
y
F
i
g
u
r
e
S
1
(
A
)
S
c
h
e
m
a
t
i
c
r
e
p
r
e
s
e
n
t
a
t
i
o
n
o
f
t
h
e
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
p
r
o
c
e
d
u
r
e
a
n
d
t
h
e
c
o
l
l
e
c
t
i
o
n
t
i
m
e
p
o
i
n
t
s
.
(
B
–
G
)
I
n
d
i
v
i
d
u
a
l
p
a
n
e
l
s
d
e
p
i
c
t
t
h
e
r
e
l
a
t
i
v
e
e
x
p
r
e
s
s
i
o
n
p
r
o
ﬁ
l
e
s
d
u
r
i
n
g
a
d
i
p
o
g
e
n
e
s
i
s
i
n
t
h
r
e
e
i
n
d
e
p
e
n
d
e
n
t
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
e
x
p
e
r
i
m
e
n
t
s
(
D
i
f
f
e
r
e
n
t
i
a
t
i
o
n
1
–
3
)
f
o
r
(
B
)
P
p
a
r
g
,
A
n
g
p
t
l
4
a
n
d
C
e
b
p
a
;
(
C
)
P
a
n
k
2
,
P
a
n
k
3
,
p
r
i
-
m
i
R
-
1
0
3
-
1
,
p
r
i
-
m
i
R
-
1
0
3
-
2
a
n
d
t
h
e
m
a
t
u
r
e
m
i
R
-
1
0
3
;
(
D
)
C
o
p
z
1
,
p
r
i
-
m
i
R
-
1
4
8
b
a
n
d
m
i
R
-
1
4
8
b
;
(
E
)
p
r
i
-
m
i
R
-
9
6
a
n
d
m
i
R
-
9
6
;
(
F
)
p
r
i
-
m
i
R
-
2
0
5
a
n
d
m
i
R
-
2
0
5
a
n
d
(
G
)
P
p
a
r
g
c
1
b
,
p
r
i
-
m
i
R
-
3
7
8
a
n
d
m
i
R
-
3
7
8
.
T
h
e
m
e
a
s
u
r
e
d
e
x
p
r
e
s
s
i
o
n
v
a
l
u
e
s
w
e
r
e
n
o
r
m
a
l
i
z
e
d
t
o
R
p
l
1
3
a
m
R
N
A
(
f
o
r
m
R
N
A
s
a
n
d
p
r
i
-
m
i
R
N
A
s
)
o
r
U
6
s
m
a
l
l
n
u
c
l
e
a
r
R
N
A
(
s
n
R
N
A
)
(
f
o
r
m
i
R
N
A
s
)
a
n
d
a
r
e
s
h
o
w
n
r
e
l
a
t
i
v
e
t
o
D
0
.
T
h
e
r
e
s
u
l
t
s
f
r
o
m
t
h
r
e
e
i
n
d
e
p
e
n
d
e
n
t
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
e
x
p
e
r
i
m
e
n
t
s
a
r
e
s
h
o
w
n
.
T
h
e
s
t
a
t
i
s
t
i
c
a
l
s
i
g
n
i
ﬁ
c
a
n
c
e
o
f
t
h
e
c
h
a
n
g
e
s
f
o
r
e
a
c
h
t
r
a
n
s
c
r
i
p
t
d
u
r
i
n
g
t
h
e
t
i
m
e
c
o
u
r
s
e
o
f
t
h
e
t
h
r
e
e
i
n
d
e
p
e
n
d
e
n
t
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
s
w
a
s
t
e
s
t
e
d
u
s
i
n
g
A
N
O
V
A
.
A
l
l
t
e
s
t
e
d
m
R
N
A
s
,
a
l
l
m
a
t
u
r
e
m
i
R
N
A
s
e
x
c
e
p
t
m
i
R
-
1
4
8
b
a
n
d
p
r
i
-
m
i
R
t
r
a
n
s
c
r
i
p
t
s
f
o
r
m
i
R
-
1
0
3
-
1
,
m
i
R
-
2
0
5
a
n
d
m
i
R
-
3
7
8
w
e
r
e
s
i
g
n
i
ﬁ
c
a
n
t
l
y
a
f
f
e
c
t
e
d
d
u
r
i
n
g
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
(
P
<
0
.
0
5
;
f
o
r
p
r
i
-
m
i
R
-
9
6
t
h
e
P
-
v
a
l
u
e
w
a
s
0
.
0
7
8
)
.
4452 Nucleic Acids Research, 2012,Vol.40, No. 10the mature miRNAs remained unaffected throughout the
experiments and only miRNAs miR-205 and miR-378
decreased clearly below the DMSO-control levels after
48h of DRB treatment (Supplementary Figure S3F and
G). These results are consistent with previous studies sug-
gesting high stability of mature miRNA transcripts (34,35)
and readily explain the observed differences in the expres-
sion proﬁles of the pri-miRNAs and their mature
counterparts.
Taken together, ﬁve candidate PPARg target miRNAs
were dynamically upregulated during 3T3-L1 differenti-
ation, most likely due to increased transcription at their
genomic loci as indicated by the induced levels of the re-
spective pri-miRNA transcripts. With the exception of
miR-103-2, the expression of all tested genes followed
that of Pparg, implicating them as possible primary
PPARg target genes.
PPARc-dependence of the candidate PPARc-target
miRNAs and their host genes
To test the PPARg-dependence of the candidate PPARg
target miRNA genes, we performed siRNA silencing of
PPARg on D6 of 3T3-L1 differentiation (Figure 3A). At
48h post-transfection the expression of both PPARg
variants had strongly decreased on the protein level
(Supplementary Figure S4) and the Pparg mRNA level
was reduced below 30% of that in cells transfected with
an unspeciﬁc control siRNA (Figure 3B). The expression
levels of the two primary PPARg target genes, Cebpa and
Angptl4, were also decreased, conﬁrming a reduced tran-
scriptional activation by PPARg.
Comparison of the two miR-103 loci showed that
pri-miR-103-1 and especially its host gene Pank3 were
downregulated by PPARg silencing, while pri-miR-103-2
and its host gene Pank2 were not affected (Figure 3C).
This also further conﬁrms miR-103-1 as the main source
of miR-103 upregulation during adipogenesis. However,
reduction in the levels of mature miR-103 could not be
detected yet at this point, most likely due to remarkably
high stability of the mature miRNA (Supplementary
Figure S3). Consistent with their moderate induction in
adipogenesis, mature miR-148b and pri-miR-148b
remained mainly unaffected by PPARg silencing, and
their host gene Copz1 was only modestly, although signiﬁ-
cantly, downregulated (Figure 3D). Pri-miR-96 was
decreased to same extent as the mature miR-96
(Figure 3E). Similarly, both pri-miR-205 and miR-205,
which were the two most strongly affected miRNA tran-
scripts tested, showed a drastic reduction down to 20–30%
of their expression level (Figure 3F). Finally, pri-miR-378,
mature miR-378 and their host gene Ppargc1b were all
signiﬁcantly downregulated by PPARg silencing
(Figure 3G).
In summary, all candidate PPARg-targeted miRNA
loci except miR-148b and miR-103-2 depend on PPARg
for their expression in mouse adipocytes. Moreover, this
dependence can be attributed to their transcriptional regu-
lation as demonstrated by the reduced levels of the
respective pri-miRNA transcripts and host genes.
Effects of RGZ on candidate PPARc target miRNAs
and their host genes
One classical approach to identify primary target genes of
ligand-dependent nuclear receptors includes short-time
treatments with agonists. Therefore, we tested treatments
of differentiating 3T3-L1 cells at D2, D4 and D6 with the
PPARg agonist RGZ and observed highest upregulation
of the known primary PPARg target genes Cebpa and
Angptl4 at D2 (Figure 4A and B and data not shown).
This is an obvious time point for RGZ treatment, since
on D2 the levels of PPARg expression have already
increased but the cells have not yet been exposed to
RGZ or high levels of endogenous ligands. To test the
RGZ response of the candidate genes we performed a
time series of RGZ treatments and collected RNA 4, 8,
12, 24 and 48h after the treatment (Figure 4A). In agree-
ment with around 24-h delay in the upregulation of
mature miRNAs observed during the differentiation
time course (Figure 2), the mature miR-378 was not
induced until after 12h of RGZ treatment and the more
stable miR-103 became induced only after 48h
(Figures 4C–G). In contrast miR-205 was signiﬁcantly
induced already 4h after RGZ treatment, reached
almost 3-fold induction by 8h and continued to accumu-
late up to 10-fold by 48h (Figure 4F). Consistently, also
pri-miR-205 showed a clear response to the agonist treat-
ment, although with a weaker fold change. Likewise,
pri-miR-103-1 and pri-miR-378 were both signiﬁcantly
induced upon PPARg activation and continued to accu-
mulate throughout the time course (Figure 4C and G),
while inductions of pri-miR-148b and pri-miR-96 as well
as their mature counterparts were either very weak or not
signiﬁcant (Figure 4D and E). Similarly to the
pri-miRNAs, the host genes of miR-103-1 and miR-378,
Pank3 and Pparg1b, were also signiﬁcantly upregulated
already after ﬁrst time points of RGZ treatment, arguing
that these genes are indeed primary PPARg targets.
Taken together, from the six candidate PPARg target
miRNA genes three, namely miR-103-1, miR-205 and
miR-378, and the two host genes Pank3 and Ppargc1b
could be conﬁrmed as PPARg targets also by upregulation
upon treatment with the PPARg ligand RGZ.
Validation of the PPARc association with PPREs on
the Pank3, Ppargc1b and miR-205 loci
In order to validate direct binding of PPARg to the regu-
latory regions of our newly identiﬁed PPARg target genes,
we performed regular ChIP assays followed by qPCR with
chromatin extracted from 3T3-L1 cells at D0 and D6 ex-
pressing either low or high levels of PPARg (Figure 5,
Supplementary Figure S4). In order to conﬁrm that the
observed enrichments are speciﬁc for PPARg, we used two
different PPARg antibodies in separate immunopreci-
pitations (one used in the previous genome-wide studies
and another independent antibody from a different
provider, see ‘Materials and Methods’ section). For this
validation we focused our efforts on the three miRNA loci
that were most responsive to RGZ, namely miR-103-1,
miR-205 and miR-378. As positive control we used the
known PPARg target gene Angptl4 and as negative
Nucleic Acids Research, 2012,Vol.40, No. 10 4453control the Pou5f1 gene, which is not signiﬁcantly
expressed in adipocytes (data not shown). Examination
of the genomic regions ±100kb from the TSS of
Angptl4 (Figure 5A), Pou5f1 (Figure 5B), Pank3
(miR-103-1) (Figure 5C) and Ppargc1b (miR-378)
(Figure 5D), and ±120kb from the TSS of miR-205
(Figure 5E) identiﬁed 8, 2, 10, 13 and 5 independent
PPARg-bound sites on each locus, respectively, when
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Figure 3. Effects of PPARg downregulation in mature mouse 3T3-L1 adipocytes on the candidate miRNAs and their host genes. (A) Schematic
representation of the experimental procedure for silencing PPARg in differentiated 3T3-L1 adipocytes. Six days differentiated 3T3-L1 cells were
transfected with siRNA speciﬁc for Pparg (siPparg) or with unspeciﬁc control siRNA (siControl). Forty-eight hours post-transfection the cells were
collected and the total RNA was extracted. (B–G) qPCR analysis of the relative expression values in siPparg transfected cells compared with
siControl transfection for (B) Pparg, Cebpa and Angptl4;( C) Pank2, Pank3, pri-miR-103-1, pri-miR-103-2 and miR-103; (D) Copz1, pri-miR-148b
and miR-148b; (E) pri-miR-96 and miR-96; (F) pri-miR-205 and miR-205 and (G) Ppargc1b, pri-miR-378 and miR-378. The measured expression
values were normalized to Rpl13a mRNA (for mRNAs and pri-miRNAs) or U6 snRNA (for miRNAs) and are shown relative to siControl, value of
which was set to 1 (indicated by dashed line). Data points indicate the mean expression values of four independent experiments and the error bars
represent SEM. One sample t-test was performed to determine the signiﬁcance of downregulation upon siPparg transfection (*P<0.05; **P<0.01;
for Cebpa, Pank3, pri-miR-96, miR-96 and miR-205 the P-values of downregulation were 0.096, 0.078, 0.097, 0.139 and 0.052, respectively).
4454 Nucleic Acids Research, 2012,Vol.40, No. 10looking at all four genome-wide datasets. To identify the
PPARg-bound sites that could correspond to direct DNA
binding of PPARg to a PPRE, we aligned the ChIP-
identiﬁed binding sites with PPREs predicted by the
REsearch algorithm (10). Predictions by REsearch are
based on PPARg binding in gel shift analysis and, in
addition to the PPRE location, provide information
about the strength of the PPARg–PPRE interaction
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Figure 4. Effects of RGZ treatment of 2 days differentiated 3T3-L1 cells on the candidate miRNAs and their host genes. (A) Experimental pro-
cedure for RGZ treatment of 2 days differentiated 3T3-L1 cells. (B–G) qPCR analysis of the relative expression values in RGZ-treated cells
compared with DMSO-treated controls for (B) Pparg, Cebpa and Angptl4; (C) Pank2, Pank3, pri-miR-103-1, pri-miR-103-2 and miR-103;
(D) Copz1, pri-miR-148b and miR-148b; (E) pri-miR-96 and miR-96; (F) pri-miR-205 and miR-205 and (G) Ppargc1b, pri-miR-378 and
miR-378. The measured expression values were normalized to Rpl13a mRNA (for mRNAs and pri-miRNAs) or U6 snRNA (for miRNAs) and
are shown relative to DMSO treatment, value of which was set to 1 (indicated by dashed line). Data points indicate the mean expression values of at
least three independent experiments and the error bars represent SEM. One sample t-test was performed to determine the signiﬁcance of upregulation
upon RGZ treatment (*P<0.05; **P<0.01; ***P<0.001).
Nucleic Acids Research, 2012,Vol.40, No. 10 4455in vitro. This ﬁltering approach reduced the number of
genomic regions to two for Angptl4, none for Pou5f1,
three for Pank3 and ﬁve for both Ppargc1b and
miR-205. For the Angptl4 gene we selected RE1Angptl4 con-
taining three predicted PPREs, one of which is a known
functional PPRE in adipocytes (28). For the Pou5f1 gene
we used its TSS region (TSSPou5f1). The three PPREs,
RE1Pank3, RE2Pank3 and RE3Pank3, are located 19, 31
and 37kb upstream from the Pank3 TSS, respectively.
RE3Pank3 in fact contains two separate PPREs located
within 200bp from each other. All three REs contain
PPREs with good in vitro binding strength for PPARg.
From the ﬁve PPARg-bound sites of the Ppargc1b locus
four contain at least two adjacent PPREs each. Two of
them, RE1Ppargc1b and RE2Ppargc1b, located 38 and 90kb
upstream from Ppargc1b TSS, were selected for
validation. RE2Ppargc1b contains two strong PPREs and
one weak PPRE while RE1Ppargc1b has only two
weak PPREs. Finally, from the ﬁve PPARg-bound sites
at miR-205 locus we chose two, RE1miR-205 and
RE2miR-205, to be validated. The sites are located at 37
and 118kb upstream from the miR-205 TSS with one
PPRE in each. The sequences and the exact locations of
the PPREs are provided in Supplementary Table S5.
In ChIP assays PPARg showed low association with
RE1Angptl4 in pre-adipocytes (D0) but in differentiated adi-
pocytes (D6) a signiﬁcant increase in enrichment to
15-fold over IgG could be observed at this genomic
region with both PPARg antibodies (Figure 5A), reﬂecting
the speciﬁc binding by PPARg during differentiation. The
enrichment of the control TSSPou5f1 remained at the back-
ground level in both conditions (Figure 5B). Importantly,
ABC D E
Figure 5. Identiﬁcation of active PPREs responsible for direct PPARg–DNA interaction and validation of the PPARg binding at the PPREs on the
Pank3, Ppargc1b and miR-205 loci by ChIP analysis. (A–E, top panel) Levels of H3K27 acetylation determined by ChIP-Seq (7) at D0, D2 and D7
of 3T3-L1 differentiation and (A–E, middle panel) PPARg-binding sites determined by ChIP-chip (3), ChIP-Seq (4,6) and ChIP-PET (5) ±100kb
around the TSS of (A) the Angptl4 positive control locus, (B) the Pou5f1 negative control locus, (C) Pank3 (miR-103-1), (D) Ppargc1b (miR-378) and
(E) ±120kb around the TSS of miR-205. In silico predicted PPREs overlapping with the ChIP binding sites are marked in red. The PPREs selected
for validation are highlighted and the primers used to amplify regions overlapping these PPREs are indicated as arrows. (A–E, lower panel) ChIP
analysis using two different PPARg antibodies from independent providers [a-PPARg (Cayman) or a-PPARg (Santa-Cruz)] and IgG as a control.
qPCR was performed with DNA immunoprecipitated from pre-adipocytes (D0) or adipocytes (D6) and using primers speciﬁc for (A) a known PPRE
on the Angptl4 locus, (B) an unrelated control region on the Pou5f1 locus, (C) three putative PPREs (RE1Pank3, RE2Pank3 and RE3Pank3) on the
Pank3 locus, (D) two clusters of putative PPREs (RE1Ppargc1b and RE2Ppargc1b) on the Ppargc1b locus and two putative PPREs (RE1miR205 and RE2
miR205) on the miR-205 locus. The measured enrichment values were normalized to 1:100 diluted input DNA. The enrichment of PPARg is shown
relative to the enrichment of IgG (indicated by dashed line). Data points indicate the mean enrichment values of at least three independent
experiments and the error bars represent SEM. One sample t-test was performed to determine the signiﬁcance of PPARg enrichment at D6
compared with D0 (*P<0.05; **P<0.01; ***P<0.001).
4456 Nucleic Acids Research, 2012,Vol.40, No. 10the enrichments of the three REs at the Pank3 locus
(Figure 5C), the two tested REs at the Ppargc1b locus
(Figure 5D) as well as RE2miR-205 (Figure 5E) all exhibited
strong and mostly signiﬁcant increases in their enrich-
ments between pre-adipocytes and adipocytes. Finally,
all enrichments were consistent between the two
antibodies, arguing that we are monitoring speciﬁc
binding of PPARg at these regions.
Since the interaction of PPARg with the selected REs
could be validated by regular ChIP assays, we were inter-
ested to see whether these regions could indeed be active
enhancers contributing to regulation of expression of the
conﬁrmed target genes. To address this possibility, we
took advantage of the recent identiﬁcation of acetylation
of lysine 27 of histone H3 (H3K27ac) as a histone modi-
ﬁcation speciﬁcally marking active enhancer regions
(36,37). Analysis of the published ChIP-Seq data from
Mikkelsen et al. (7) for the level of H3K27ac at our loci
of interest during 3T3-L1 differentiation conﬁrmed
that all of our tested REs, except RE3Pank3, are
accumulating H3K27 acetylation during adipogenesis
(Figure 5, top panel). These data argue that the identiﬁed
PPREs can serve as speciﬁc binding sites for PPARg
during adipogenesis and contribute as active enhancers
to the regulation of the identiﬁed primary PPARg target
miRNA genes.
DISCUSSION
This study was performed with the aim to identify miRNA
genes that are primary nuclear receptor targets. Since
miRNA genes often serve as critical developmental
switches and are regulated in differentiation processes
(23), we have chosen adipogenesis as an experimental
system, where a dominant role is played by the nuclear
receptor PPARg (2). We selected the mouse 3T3-L1 cells
as a cellular model, for which far more public data are
available than for any comparable human system (3–6,26).
Our approach for the identiﬁcation of miRNA genes that
are primary PPARg targets was to integrate genome-wide
data about PPARg binding with recent information on
TSS locations of miRNA genes.
Although the genome-wide PPARg location data were
obtained with the same cellular model and the same
antibody, we realized that only the minority of the
PPARg-bound sites are conﬁrmed in at least three of the
four datasets. The integration of the four datasets sug-
gested that for 140 miRNAs a PPARg-bound site is
located within 50-kb distance from their TSS in at least
one of the datasets. Since PPARg is signiﬁcantly
upregulated during adipogenesis, a ﬁltering of the 140
miRNAs for those that are more than 2-fold upregulated
during 3T3-L1 differentiation, reduced the number to 19
miRNAs encoded by 22 miRNA genes that form the list
of putative PPARg targets. However, the condition that
PPARg binding at the genomic region had to be conﬁrmed
in at least three of the four datasets, reduced the list to six
miRNA genes miR-103-1, miR-103-2, miR-148b,
miR-183/96/182, miR-205 and miR-378. Both a detailed
time course analysis of the upregulation of these miRNAs
as well as PPARg silencing in differentiated adipocytes
excluded only miR-103-2 and miR-148b from this list of
putative primary PPARg target genes. Still, PPARg might
inﬂuence also the transcription of miR-103-2 and
miR-148b loci, although not as potently as for the other
tested loci, or for example in a different cellular context.
Importantly, the genes encoding miR-103-1, miR-205 and
miR-378 could be conﬁrmed as classical PPARg targets
also by RGZ treatments. Interestingly, the host genes of
these miRNAs, Pank3 and Ppargc1b, are also primary
PPARg target genes, which have not yet been reported
as such. For Pank3 (miR-103-1) we validated three
genomic PPARg binding sites that overlap with in silico
predicted PPREs 19, 31 and 37kb upstream from the
Pank3 TSS, for the Ppargc1b (miR-378) locus two
PPARg locations with adjacent PPREs 90 and 38kb
upstream of the TSS, and for the miR-205 locus one
PPARg binding site with PPRE at 118-kb upstream of
the TSS. The future work to identify the exact PPRE
sequences responsible for target gene regulation, especially
for REs containing multiple PPREs, will require detailed
experiments applying reporter gene assays or optimally
zinc-ﬁnger nuclease-mediated targeting of individual en-
dogenous PPREs. However, by applying the genome-wide
mapping of H3K27ac, a histone modiﬁcation speciﬁcally
marking the active enhancer regions, we have already
shown that most of the validated PPARg-bound sites
are accumulating increased levels of H3K27ac, suggesting
that these enhancers are actively contributing to the regu-
lation of the identiﬁed target genes.
Since Lefterova et al. (3) have shown PPARg to
co-localize with the transcription factor CEBPa in
differentiated 3T3-L1 cells, we took advantage of this
dataset and compared CEBPa-bound sites with the
PPARg-bound sites at miRNA loci. In most of them (29
of the 52) CEBPa was found in <1kb distance from the
respective PPARg-bound sites (data not shown).
Moreover, all of the six candidate miRNA loci except
miR-205 had their regulatory regions co-occupied by
PPARg and CEBPa, suggesting that the two transcription
factors might induce different miRNA genes in a com-
binatorial manner, similarly to protein coding genes
(data not shown) (3).
Although most of our candidate miRNA genes depend
on PPARg for their expression in adipocytes, we found
that the dynamics of their expression changes, and those
of their host genes, varied during adipogenesis. This is
perhaps most evident for miR-103, which exhibits a
delay in its upregulation when compared with the host
gene Pank3. While this observation might be mainly
explained by different processing of the two mature tran-
scripts, the usage of alternative TSSs or differential stabil-
ity of the two mature transcripts could also play a role.
Histone H3 lysine 4 trimethylation (H3K4me3) is an epi-
genetic modiﬁcation known to mark active TSSs. Based
on genome-wide mapping of H3K4me3 in mouse 3T3-L1
cells, only one TSS exists at the Pank3 locus during
adipogenesis (7). This argues that the differences
observed in the expression dynamics are more likely to
be explained by the dissimilar stabilities of the mature
transcripts, rather than alternative TSS usage. Indeed,
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Figure S3), miRNAs were recently estimated to possess
an average half-life of almost 5 days (35). This is 12
times longer than the median half-life of mRNAs, which
is 10h (38). When a mature transcript exhibits a low turn-
over, it accumulates higher basal expression levels, even
upon low levels of basal transcription. Consequently,
upon increased expression such transcript can exhibit rela-
tively low fold inductions with slower accumulation rate
although the extent of transcriptional output is compar-
able with that of a lower stability transcript. Therefore, it
is likely that the different dynamics of miR-103 (and other
miRNAs) are explained by its higher stability compared
with the mature Pank3 mRNA (Supplementary
Figure S3). Consistently, we found that 48h knock-down
of PPARg had no signiﬁcant effects on mature miR-103
and its response to treatments with RGZ occurred only
after 48h, while the host gene Pank3 clearly responded
already after 4h.
Transcriptional regulation by PPARg is both necessary
and sufﬁcient for adipogenesis and therefore its primary
target genes, including the miRNA genes described here,
might play a critical role or at least contribute to success-
ful adipogenesis. Indeed, miR-103 has already been
described as highly induced in primary mouse adipocytes
and as capable of accelerating adipogenesis (26). miR-103
belongs to a family of three miRNAs, miR-103-1,
miR-103-2 and miR-107, that have almost identical
sequences and are transcribed together with their host
genes Pank3, Pank2 and Pank1, respectively (22,29).
Interestingly, in addition to the two miR-103 loci also
miR-107 was identiﬁed as a putative PPARg target gene
in our initial analysis (Figure 1A) and its host gene Pank1
has been described as a primary PPARa target in human
liver (39). Importantly, recent data from Trajkovski et al.
(40) demonstrated that silencing of miR-103 and miR-107
in the adipose tissue of mice leads to reduced fat levels,
but in contradiction to previous in vitro data, not via in-
hibition of adipogenesis. Instead, lowered levels of
the miRNAs increased the insulin sensitivity of the adipo-
cytes, a phenomenon linked to increased number of
smaller sized adipocytes. Therefore, our data, together
with abovementioned ﬁndings, create direct links
between PPARs, miR-103/107 family miRNAs and
insulin sensitivity.
Unlike miR-103, the miR-183/96/182 cluster has
not been functionally connected to adipogenesis so far.
However, based on the very robust induction that we
observed during 3T3-L1 adipogenesis, the members of
this cluster are likely to contribute to the biology of
mature adipocytes. Treatment with insulin alone was
recently shown to downregulate miR-183 levels in
3T3-L1 adipocytes (41). However, during adipogenesis
the cluster becomes upregulated in a PPARg-dependent
manner, despite the presence of insulin in the differenti-
ation medium. Therefore, it is probable that the expres-
sion of the miR-183/96/182 cluster is under combinatorial
regulation of several transcription factors and pathways
that together lead to the clusters increased expression in
adipocytes.
By far the highest induced miRNA tested in our
analysis was miR-205. The exact signiﬁcance of this induc-
tion for adipogenesis remains unclear for now. However,
the list of predicted target mRNAs for miR-205 includes,
for example, Runx2 (TargetScan 5.2), a transcript
encoding a transcription factor with an important role in
favoring osteoblastogenesis over adipogenesis during mes-
enchymal stem cell differentiation (42). High levels of
PPARg are known to suppress RUNX2 protein expres-
sion and induction of miR-205 might serve as a mechan-
ism to achieve this suppression. Indeed, Zhang et al. (43)
recently showed that miR-205 can attenuate RUNX2
protein accumulation together with nine other miRNAs
in mouse osteoblasts. However, our preliminary experi-
ments have so far failed to demonstrate reduction in
Runx2 mRNA levels upon miR-205 overexpression in
pre-adipocytes (data not shown), suggesting that a com-
binatorial function of multiple miRNAs might be required
for robust regulation of Runx2 at the mRNA level.
Consistently, we were so far unable to demonstrate any
signiﬁcant impact of miR-205 overexpression on early
adipogenesis in general, as measured by the expression
levels of the known adipocyte marker genes such
as Pparg and Cebpa (data not shown). Proteome-
or transcriptome-wide analysis upon gain- or loss-of-
function of miR-205 would be needed to reveal the
primary targets mRNAs and pathways regulated by the
robust induction of miR-205 during adipogenesis.
Interestingly, we also found miR-378 and its host gene
Ppargc1b as primary PPARg targets in adipocytes.
miR-378 can induce lipogenesis and expression of lipogen-
ic genes, when overexpressed during adipogenesis of ST2
mesenchymal precursors (44). Moreover, Ppargc1b is a
known transcriptional co-activator responsible for
inducing the target genes of numerous transcription
factors (for example, sterol response element binding
proteins, liver X receptors and PPARs) that are involved
in regulation of lipogenesis and related processes (31).
This suggests that PPARg may induce both miR-378
and Ppargc1b, in order to allow both to function syner-
gistically in the regulation of lipid metabolism. Impor-
tantly, this induction is not limited to mouse 3T3-L1
cells as miR-378 was recently identiﬁed as the most
highly upregulated miRNA during the differentiation of
both mouse and human primary adipocytes (26,45).
In addition to miRNAs discussed above, a more
detailed analysis of our initial list of putative PPARg
target miRNA genes will lead to a more complete list of
the true PPARg target miRNAs. Revealing the role of
these miRNAs in adipogenesis and identiﬁcation of
their primary target mRNAs will be important for their
integration to the regulatory networks governing
adipogenesis.
SUPPLEMENTARY DATA
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Supplementary Tables S1–S5 and Supplementary Figures
S1–S4.
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